Cardinal Health (NYSE:CAH) Price Target Raised to $260.00

Cardinal Health (NYSE:CAH) had its price objective lifted by Evercore ISI from $250.00 to $260.00 in a report published on Friday morning,MarketScreener reports.

A number of other equities research analysts have also recently commented on CAH. Weiss Ratings reissued a “buy (b)” rating on shares of Cardinal Health in a report on Wednesday, January 21st. Mizuho boosted their price target on Cardinal Health from $222.00 to $235.00 and gave the stock an “outperform” rating in a report on Friday. Jefferies Financial Group upped their price target on Cardinal Health from $220.00 to $270.00 and gave the stock a “buy” rating in a research note on Thursday, January 22nd. UBS Group set a $260.00 price objective on shares of Cardinal Health and gave the company a “buy” rating in a research report on Friday. Finally, Evercore restated an “outperform” rating and set a $260.00 target price on shares of Cardinal Health in a research report on Thursday. Fifteen equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $241.27.

Cardinal Health Stock Down 0.1%

Shares of NYSE:CAH opened at $226.85 on Friday. The company’s fifty day moving average is $206.92 and its 200 day moving average is $180.29. The stock has a market cap of $53.38 billion, a PE ratio of 32.64, a PEG ratio of 1.48 and a beta of 0.64. Cardinal Health has a 52 week low of $120.72 and a 52 week high of $230.81.

Cardinal Health (NYSE:CAH) last released its earnings results on Thursday, February 5th. The company reported $2.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.31 by $0.32. The company had revenue of $65.63 billion during the quarter, compared to analyst estimates of $64.88 billion. Cardinal Health had a net margin of 0.68% and a negative return on equity of 92.50%. The firm’s quarterly revenue was up 18.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.93 EPS. Sell-side analysts anticipate that Cardinal Health will post 7.95 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in CAH. Vanguard Group Inc. increased its holdings in shares of Cardinal Health by 2.0% in the 4th quarter. Vanguard Group Inc. now owns 31,441,258 shares of the company’s stock valued at $6,461,179,000 after acquiring an additional 617,775 shares during the period. Geode Capital Management LLC grew its stake in Cardinal Health by 3.3% in the second quarter. Geode Capital Management LLC now owns 6,389,049 shares of the company’s stock valued at $1,069,005,000 after purchasing an additional 205,539 shares during the last quarter. Wellington Management Group LLP raised its holdings in Cardinal Health by 153.2% in the third quarter. Wellington Management Group LLP now owns 5,804,090 shares of the company’s stock worth $911,010,000 after purchasing an additional 3,511,579 shares in the last quarter. Bank of America Corp DE lifted its position in shares of Cardinal Health by 3.2% during the third quarter. Bank of America Corp DE now owns 3,592,775 shares of the company’s stock valued at $563,922,000 after buying an additional 111,582 shares during the last quarter. Finally, Invesco Ltd. lifted its position in shares of Cardinal Health by 14.7% during the third quarter. Invesco Ltd. now owns 3,483,207 shares of the company’s stock valued at $546,724,000 after buying an additional 445,425 shares during the last quarter. Hedge funds and other institutional investors own 87.17% of the company’s stock.

Cardinal Health News Summary

Here are the key news stories impacting Cardinal Health this week:

• Positive Sentiment: Q2 results and raised outlook — Cardinal reported Q2 FY2026 revenue up ~19% to $65.6B and non‑GAAP EPS of $2.63 (beat), and raised fiscal‑year non‑GAAP EPS guidance to $10.15–$10.35; management cited strong specialty medicine demand and improved segment performance. PR Newswire
• Positive Sentiment: Analyst upgrade and price‑target lift — Leerink Partners raised its price target from $240 to $268 and kept an outperform rating, signaling more upside from current levels. MarketScreener
• Positive Sentiment: Street commentary and momentum coverage — Multiple outlets (Barron’s, Reuters, Zacks, TipRanks, 24/7 Wall St.) highlight the beat, raised guidance and accelerating specialty drug volumes, which has driven momentum interest in the stock. Examples: Reuters coverage on the outlook and Barron’s note on guidance lifts. Reuters
• Neutral Sentiment: Earnings call & transcripts available — Management commentary and slides from the Q2 call confirm the drivers behind the beat (specialty medicine, margin expansion, buybacks); these provide detail but no new surprises beyond the release. MSN Transcript
• Neutral Sentiment: Momentum stock analysis — Zacks highlights style‑score based momentum attributes, which can attract technical and quant funds but also increase volatility. Zacks
• Negative Sentiment: Valuation and historical ROE signal — After the rally the stock trades at an elevated P/E (~34x) and company data show a negative trailing return on equity metric, which could concern value‑focused investors and limit upside absent continued execution. Background valuation metrics

About Cardinal Health

Cardinal Health is a multinational healthcare services and products company headquartered in Dublin, Ohio. Tracing its roots to the early 1970s, the company has grown into a major provider of supply chain and distribution services for the healthcare sector. Cardinal Health operates across a range of service lines that support hospitals, health systems, pharmacies, physician offices and clinical laboratories.

The company’s core activities include the wholesale distribution of branded and generic pharmaceuticals, the supply and distribution of medical-surgical products, and the provision of logistics and inventory management solutions.